A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

BACKGROUND: Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseli...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Heart Fail
Autores principales: McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna M., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Trial Designs
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6607736/
https://ncbi.nlm.nih.gov/pubmed/30895697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1432
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares